Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience.

IF 1.2 Q4 PHARMACOLOGY & PHARMACY
Akihiro Uchiike, Haruka Kono, Katsuhiro Miura, Tatsuya Hayama, Daisuke Tsutsumi, Shinya Tsuboi, Susumu Ohtsuka, Shinji Hidaka
{"title":"Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience.","authors":"Akihiro Uchiike,&nbsp;Haruka Kono,&nbsp;Katsuhiro Miura,&nbsp;Tatsuya Hayama,&nbsp;Daisuke Tsutsumi,&nbsp;Shinya Tsuboi,&nbsp;Susumu Ohtsuka,&nbsp;Shinji Hidaka","doi":"10.1186/s40780-023-00293-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Olanzapine treatment prevents chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). However, its role in the secondary prevention of breakthrough CINV in real-world cancer care should be further evaluated.</p><p><strong>Method: </strong>We conducted a retrospective study on patients receiving olanzapine to prevent breakthrough CINV refractory to standard antiemetic therapy. The major outcome was improvement in CINV, defined as any downgrade in CINV symptoms, according to the Common Terminology Criteria for Adverse Events. Comprete response was defined as no symptoms in CINV, i.e., Grade 0. These outcomes were compared in the HEC versus non-HEC groups and the standard- (5 or 10 mg/day) versus low- (2.5 mg/day) dose groups. The other outcome measurement was adverse events (AEs).</p><p><strong>Results: </strong>We analyzed 127 patients, including 92 women, with a median age of 50 years (range: 19-89 years). Baseline CINV severity was grade 1, 2, and 3 in 18%, 69%, and 13% of the patients, respectively. After prophylaxis with olanzapine at doses of 2.5, 5, or 10 mg/day, improvement was observed in 105 (83%) patients, with a complete response in 42 patients (33%). The improvement and complete remission rates for the HEC (n = 96) and non-HEC (n = 31) groups were 86% and 71% (p = 0.048) versus 38% and 19% (p = 0.062), respectively. The rates for the standard- (n = 98) and low- (n = 29) dose groups were 86% and 82% (p = 0.568) versus 28% and 52% (p = 0.015), respectively. Thirty-four patients (27%) experienced olanzapine-related AEs, mainly somnolence (n = 28). Grade 3 or higher AEs were not observed.</p><p><strong>Conclusion: </strong>Our study results support the clinical application of olanzapine for the secondary prevention of breakthrough CINV.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391758/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Health Care and Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40780-023-00293-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Olanzapine treatment prevents chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). However, its role in the secondary prevention of breakthrough CINV in real-world cancer care should be further evaluated.

Method: We conducted a retrospective study on patients receiving olanzapine to prevent breakthrough CINV refractory to standard antiemetic therapy. The major outcome was improvement in CINV, defined as any downgrade in CINV symptoms, according to the Common Terminology Criteria for Adverse Events. Comprete response was defined as no symptoms in CINV, i.e., Grade 0. These outcomes were compared in the HEC versus non-HEC groups and the standard- (5 or 10 mg/day) versus low- (2.5 mg/day) dose groups. The other outcome measurement was adverse events (AEs).

Results: We analyzed 127 patients, including 92 women, with a median age of 50 years (range: 19-89 years). Baseline CINV severity was grade 1, 2, and 3 in 18%, 69%, and 13% of the patients, respectively. After prophylaxis with olanzapine at doses of 2.5, 5, or 10 mg/day, improvement was observed in 105 (83%) patients, with a complete response in 42 patients (33%). The improvement and complete remission rates for the HEC (n = 96) and non-HEC (n = 31) groups were 86% and 71% (p = 0.048) versus 38% and 19% (p = 0.062), respectively. The rates for the standard- (n = 98) and low- (n = 29) dose groups were 86% and 82% (p = 0.568) versus 28% and 52% (p = 0.015), respectively. Thirty-four patients (27%) experienced olanzapine-related AEs, mainly somnolence (n = 28). Grade 3 or higher AEs were not observed.

Conclusion: Our study results support the clinical application of olanzapine for the secondary prevention of breakthrough CINV.

Abstract Image

奥氮平治疗有效缓解突破性化疗引起的恶心和呕吐:真实世界的体验。
背景:奥氮平治疗可预防接受高度致吐性化疗(HEC)患者化疗引起的恶心和呕吐(CINV)。然而,在现实世界的癌症治疗中,它在突破性CINV二级预防中的作用有待进一步评估。方法:我们对接受奥氮平治疗的患者进行回顾性研究,以防止突破CINV对标准止吐治疗的难治性。根据不良事件通用术语标准,主要结果是CINV的改善,定义为CINV症状的任何降低。完全缓解被定义为无CINV症状,即0级。这些结果在HEC组和非HEC组以及标准剂量组(5或10毫克/天)和低剂量组(2.5毫克/天)中进行了比较。另一个结果测量是不良事件(ae)。结果:我们分析了127例患者,其中包括92例女性,中位年龄为50岁(范围:19-89岁)。基线CINV严重程度分别为18%、69%和13%的患者为1级、2级和3级。在给予剂量为2.5、5或10mg /天的奥氮平预防治疗后,105例(83%)患者出现改善,42例(33%)患者出现完全缓解。HEC组(n = 96)和非HEC组(n = 31)的改善率和完全缓解率分别为86%和71% (p = 0.048)和38%和19% (p = 0.062)。标准剂量组(n = 98)和低剂量组(n = 29)的发生率分别为86%和82% (p = 0.568)和28%和52% (p = 0.015)。34例(27%)患者出现与奥氮平相关的不良事件,主要是嗜睡(n = 28)。未观察到3级或更高的ae。结论:本研究结果支持奥氮平在突破性CINV二级预防中的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
29
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信